A simplified prognostic score for T-cell large granular lymphocyte leukaemia

Ann Med. 2023;55(2):2258899. doi: 10.1080/07853890.2023.2258899. Epub 2023 Oct 6.

Abstract

Background: T-cell large granular lymphocyte leukaemia (T-LGLL) generally has a favourable prognosis, but a small proportion of patients are facing a relatively short survival time. This study aimed to identify clinical factors associated with survival in patients with T-LGLL and develop a predictive model for guiding therapeutic decision-making.

Materials and methods: We conducted a retrospective study on 120 patients with T-LGLL. Lasso regression was performed for feature selection followed by univariate and multivariate Cox regression analysis. A decision tree algorithm was employed to construct a model for predicting overall survival (OS) in T-LGLL.

Results: The median age of diagnosis for the entire cohort was 59 years, and 76.7% of patients reported disease-related symptoms. After a median follow-up of 75 months, the median OS was not reached. The 5-year OS rate was 82.2% and the 10-year OS rate was 63.8%. Multivariate analysis revealed that an Eastern Cooperative Oncology Group performance status over two and a platelet count below 100 × 109/L were independently associated with worse OS, leading to the development of a simplified decision tree model. The model's performance was adequate when internally validated. The median OS of the high- and intermediate-risk- risk groups was 43 and 100 months respectively, whereas the median OS of the low-risk group was not reached. Furthermore, we found that immunosuppressive agent-based conventional treatment was unsatisfactory for our high-risk patients.

Conclusions: Our model is an easily applicable clinical scoring system for predicting OS in patients with T-LGLL. However, external validation is essential before implementing it widely.

Keywords: Leukaemia; decision tree; lymphoproliferative disorders; prognosis; survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Leukemia, Large Granular Lymphocytic* / diagnosis
  • Middle Aged
  • Prognosis
  • Retrospective Studies

Grants and funding

This work was supported by National Natural Science Foundation of China [82100211]; National Science and Technology Major Project [2018ZX09734-007]; Translational Research Grant of NCRCH [2020ZKZB01]; Beijing Xisike Clinical Oncology Research Foundation [Y-Roche2019/2-0090]; Science Foundation Project of Ili & Jiangsu Joint Institute of Health [yl2021ms04]; Science and Technology Development Fund Project of Pukou branch of Jiangsu People’s hospital [KJ2021-4]; and Jiangsu Province Hospital (the First Affiliated Hospital with Nanjing Medical University) Clinical Capacity Enhancement Project [JSPH-MB-2021-9].